JPWO2022200982A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022200982A5 JPWO2022200982A5 JP2023557691A JP2023557691A JPWO2022200982A5 JP WO2022200982 A5 JPWO2022200982 A5 JP WO2022200982A5 JP 2023557691 A JP2023557691 A JP 2023557691A JP 2023557691 A JP2023557691 A JP 2023557691A JP WO2022200982 A5 JPWO2022200982 A5 JP WO2022200982A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- acceptable salt
- pharmaceutical composition
- talazoparib
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims 30
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- HWGQMRYQVZSGDQ-HZPDHXFCSA-N chembl3137320 Chemical compound CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 HWGQMRYQVZSGDQ-HZPDHXFCSA-N 0.000 claims 14
- 229950004550 talazoparib Drugs 0.000 claims 14
- 229960004671 enzalutamide Drugs 0.000 claims 10
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 claims 10
- 238000000034 method Methods 0.000 claims 8
- 230000002280 anti-androgenic effect Effects 0.000 claims 7
- 239000000051 antiandrogen Substances 0.000 claims 7
- 230000005971 DNA damage repair Effects 0.000 claims 5
- 206010064571 Gene mutation Diseases 0.000 claims 5
- 206010060862 Prostate cancer Diseases 0.000 claims 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 5
- 230000001394 metastastic effect Effects 0.000 claims 5
- 206010061289 metastatic neoplasm Diseases 0.000 claims 5
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 4
- 238000011284 combination treatment Methods 0.000 claims 4
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 229940041181 antineoplastic drug Drugs 0.000 claims 3
- 108700012941 GNRH1 Proteins 0.000 claims 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 2
- 239000000556 agonist Substances 0.000 claims 2
- 238000009167 androgen deprivation therapy Methods 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000037819 metastatic cancer Diseases 0.000 claims 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 108700020463 BRCA1 Proteins 0.000 claims 1
- 102000036365 BRCA1 Human genes 0.000 claims 1
- 101150072950 BRCA1 gene Proteins 0.000 claims 1
- 108700020462 BRCA2 Proteins 0.000 claims 1
- 102000052609 BRCA2 Human genes 0.000 claims 1
- 101150008921 Brca2 gene Proteins 0.000 claims 1
- 102100038111 Cyclin-dependent kinase 12 Human genes 0.000 claims 1
- 102100034484 DNA repair protein RAD51 homolog 3 Human genes 0.000 claims 1
- 102000009095 Fanconi Anemia Complementation Group A protein Human genes 0.000 claims 1
- 108010087740 Fanconi Anemia Complementation Group A protein Proteins 0.000 claims 1
- 108010067741 Fanconi Anemia Complementation Group N protein Proteins 0.000 claims 1
- 102000016627 Fanconi Anemia Complementation Group N protein Human genes 0.000 claims 1
- 101000785776 Homo sapiens Artemin Proteins 0.000 claims 1
- 101000884345 Homo sapiens Cyclin-dependent kinase 12 Proteins 0.000 claims 1
- 101001132271 Homo sapiens DNA repair protein RAD51 homolog 3 Proteins 0.000 claims 1
- 101000981336 Homo sapiens Nibrin Proteins 0.000 claims 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 claims 1
- 102000046961 MRE11 Homologue Human genes 0.000 claims 1
- 108700019589 MRE11 Homologue Proteins 0.000 claims 1
- 102000013609 MutL Protein Homolog 1 Human genes 0.000 claims 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 claims 1
- JSFOGZGIBIQRPU-UHFFFAOYSA-N N-desmethylenzalutamide Chemical compound O=C1C(C)(C)N(C=2C=C(F)C(C(N)=O)=CC=2)C(=S)N1C1=CC=C(C#N)C(C(F)(F)F)=C1 JSFOGZGIBIQRPU-UHFFFAOYSA-N 0.000 claims 1
- 102100024403 Nibrin Human genes 0.000 claims 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 claims 1
- 229960004103 abiraterone acetate Drugs 0.000 claims 1
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 claims 1
- 102000001307 androgen receptors Human genes 0.000 claims 1
- 108010080146 androgen receptors Proteins 0.000 claims 1
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- HJBWBFZLDZWPHF-UHFFFAOYSA-N apalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C2(CCC2)C(=O)N(C=2C=C(C(C#N)=NC=2)C(F)(F)F)C1=S HJBWBFZLDZWPHF-UHFFFAOYSA-N 0.000 claims 1
- 229950007511 apalutamide Drugs 0.000 claims 1
- 230000002146 bilateral effect Effects 0.000 claims 1
- QUQKKHBYEFLEHK-QNBGGDODSA-N chembl3137318 Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CN1N=CN=C1[C@H]([C@H](N1)C=2C=CC(F)=CC=2)C2=NNC(=O)C3=C2C1=CC(F)=C3 QUQKKHBYEFLEHK-QNBGGDODSA-N 0.000 claims 1
- 230000002301 combined effect Effects 0.000 claims 1
- 229950001379 darolutamide Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 101150071637 mre11 gene Proteins 0.000 claims 1
- BLIJXOOIHRSQRB-PXYINDEMSA-N n-[(2s)-1-[3-(3-chloro-4-cyanophenyl)pyrazol-1-yl]propan-2-yl]-5-(1-hydroxyethyl)-1h-pyrazole-3-carboxamide Chemical compound C([C@H](C)NC(=O)C=1NN=C(C=1)C(C)O)N(N=1)C=CC=1C1=CC=C(C#N)C(Cl)=C1 BLIJXOOIHRSQRB-PXYINDEMSA-N 0.000 claims 1
- 238000011474 orchiectomy Methods 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 229940124652 talazoparib tosylate Drugs 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163165723P | 2021-03-24 | 2021-03-24 | |
| US63/165,723 | 2021-03-24 | ||
| US202163282163P | 2021-11-22 | 2021-11-22 | |
| US63/282,163 | 2021-11-22 | ||
| US202263317368P | 2022-03-07 | 2022-03-07 | |
| US63/317,368 | 2022-03-07 | ||
| PCT/IB2022/052536 WO2022200982A1 (en) | 2021-03-24 | 2022-03-21 | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024510666A JP2024510666A (ja) | 2024-03-08 |
| JP2024510666A5 JP2024510666A5 (https=) | 2025-03-31 |
| JPWO2022200982A5 true JPWO2022200982A5 (https=) | 2025-03-31 |
Family
ID=80952181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023557691A Pending JP2024510666A (ja) | 2021-03-24 | 2022-03-21 | Ｄｄｒ遺伝子変異転移性去勢感受性前立腺がんを処置するためのタラゾパリブおよび抗アンドロゲンの組合せ |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240180906A1 (https=) |
| EP (1) | EP4313034A1 (https=) |
| JP (1) | JP2024510666A (https=) |
| KR (1) | KR20230159510A (https=) |
| AU (2) | AU2022244439A1 (https=) |
| BR (1) | BR112023018906A2 (https=) |
| CA (1) | CA3214316A1 (https=) |
| MX (1) | MX2023011294A (https=) |
| WO (1) | WO2022200982A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI883565B (zh) | 2022-10-02 | 2025-05-11 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0100172B1 (en) | 1982-07-23 | 1987-08-12 | Imperial Chemical Industries Plc | Amide derivatives |
| US5604213A (en) | 1992-03-31 | 1997-02-18 | British Technology Group Limited | 17-substituted steroids useful in cancer treatment |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| JP4644737B2 (ja) | 2005-05-13 | 2011-03-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ジアリールヒダントイン化合物 |
| LT2656842T (lt) | 2006-03-27 | 2016-09-26 | The Regents Of The University Of California | Androgeno receptoriaus moduliatorius, skirtas prostatos vėžio ir su androgeno receptoriumi susijusių ligų gydymui |
| KR101456722B1 (ko) | 2006-03-29 | 2014-10-31 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 디아릴티오히단토인 화합물 |
| TWI469971B (zh) | 2007-10-26 | 2015-01-21 | Univ California | 二芳基乙內醯脲類化合物 |
| ES2625817T3 (es) | 2008-08-06 | 2017-07-20 | Medivation Technologies, Inc. | Inhibidores de tipo Dihidropiridoftalazinona de poli(ADP-ribosa)polimerasa (PARP) |
| NZ594741A (en) | 2009-02-24 | 2014-03-28 | Medivation Prostate Therapeutics Inc | Specific diarylhydantoin and diarylthiohydantoin compounds |
| EP2416657A4 (en) | 2009-04-09 | 2012-09-05 | Medivation Prostate Therapeutics Inc | COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF |
| WO2011044327A1 (en) | 2009-10-07 | 2011-04-14 | Medivation Prostate Therapeutics, Inc. | Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| CA2787844C (en) | 2010-02-03 | 2019-08-27 | Biomarin Pharmaceutical Inc. | Dihydropyridophthalazinone inhibitors of poly(adp-ribose) polymerase (parp) for use in treatment of diseases associated with a pten deficiency |
| PT2533640T (pt) | 2010-02-08 | 2017-01-03 | Medivation Technologies Inc | Processos de síntese de derivados de di-hidropiridoftalazinona |
| NZ609490A (en) | 2010-10-21 | 2015-06-26 | Biomarin Pharm Inc | Crystalline (8s,9r)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1h-1,2,4-triazol-5-yl)-8,9-dihydro-2h-pyrido[4,3,2-de]phthalazin-3(7h)-one tosylate salt |
| TW201605814A (zh) | 2013-11-07 | 2016-02-16 | 拜奧馬林製藥公司 | 用於合成經保護之ｎ－烷基三唑甲醛的三唑中間體 |
| SG11201700734RA (en) | 2014-07-31 | 2017-02-27 | Medivation Technologies Inc | Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them |
| CN108883115A (zh) | 2015-10-26 | 2018-11-23 | 麦迪韦逊科技有限责任公司 | 用parp抑制剂治疗小细胞肺癌 |
| WO2018191141A1 (en) * | 2017-04-13 | 2018-10-18 | Janssen Pharmaceutica Nv | Combination therapy for prostate cancer |
| KR20200071097A (ko) * | 2017-10-13 | 2020-06-18 | 메르크 파텐트 게엠베하 | Parp 억제제 및 pd-1 축 결합 길항제의 조합 |
-
2022
- 2022-03-21 BR BR112023018906A patent/BR112023018906A2/pt unknown
- 2022-03-21 EP EP22713055.6A patent/EP4313034A1/en active Pending
- 2022-03-21 AU AU2022244439A patent/AU2022244439A1/en not_active Abandoned
- 2022-03-21 MX MX2023011294A patent/MX2023011294A/es unknown
- 2022-03-21 JP JP2023557691A patent/JP2024510666A/ja active Pending
- 2022-03-21 US US18/283,634 patent/US20240180906A1/en active Pending
- 2022-03-21 CA CA3214316A patent/CA3214316A1/en active Pending
- 2022-03-21 WO PCT/IB2022/052536 patent/WO2022200982A1/en not_active Ceased
- 2022-03-21 KR KR1020237035680A patent/KR20230159510A/ko active Pending
-
2025
- 2025-07-30 AU AU2025210784A patent/AU2025210784A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023174661A5 (https=) | ||
| JP2023513015A (ja) | 異常な細胞成長を処置するための併用療法 | |
| Bahl et al. | Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents | |
| CN104997808A (zh) | 用于治疗癌症的方法和组合物 | |
| JP2021169474A (ja) | がんの処置において使用するための、Ｎｏｔｃｈ阻害剤およびＰＩ３Ｋ／ｍＴＯＲ阻害剤を用いた併用療法 | |
| JP2010043114A (ja) | 腫瘍転移および癌の治療 | |
| CA3080644A1 (en) | Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer | |
| WO2004014426A1 (en) | Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer | |
| CN115487187A (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
| US20240180906A1 (en) | Combination of Talazoparib and an Anti-Androgen for the Treatment of DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer | |
| JP2024161428A (ja) | 転移性去勢感受性前立腺癌の治療のための抗アンドロゲン剤 | |
| EP4633629A1 (en) | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer | |
| CN104470509A (zh) | 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 | |
| US11000518B2 (en) | Use of combination of VEGFR inhibitor and PARP inhibitor in preparation of medicament for treating gastric cancer | |
| JPWO2022200982A5 (https=) | ||
| CN111728974B (zh) | 西奥罗尼用于小细胞肺癌的治疗 | |
| JP2023542473A (ja) | 併用薬抗がん治療 | |
| CN104968340A (zh) | 治疗肝脏疾病或病状的用途和方法 | |
| JPH1045589A (ja) | テモゾロミドによる改良されたガンの処置 | |
| CN112533600A (zh) | 用于治疗小细胞肺癌的喹啉衍生物 | |
| Deshpande et al. | The Expendables: Overlooked Medications with Anti-Cancer Properties | |
| WO2023281413A1 (en) | Methods and dosing regimens comprising pf-06873600 for the treatment of cancer | |
| CN111065395B (zh) | 用于治疗神经内分泌肿瘤的喹啉衍生物 | |
| JPWO2023035611A5 (https=) | ||
| Small et al. | Pyrazoloacridine for the treatment of hormone-refractory prostate cancer |